Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease

References

• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21: 943–960.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological disease, solid tumors and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439–449.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007;139:70–80.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Sullivan KM, Thomas ED, et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J Clin Oncol 1985;3:1490–1494.
   PubMed Web of Science ®Google Scholar
• Phillips GL, Reece MJ, Barnett JM, et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 1989;7:1039–1045.
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's disease. J Clin Oncol 2001;19:4314–4321.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649–653.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993;11:2342–2350.
   PubMed Web of Science ®Google Scholar
• Gajewski JL, Phillips GL, Sobcinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572–578.
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996;14:1291–1296.
   PubMed Web of Science ®Google Scholar
• Sureda A, Robinson S, Cananls C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's Lymphoma: an analysis from the lymphoma working party of the European Group for blood and marrow transplantation. J Clin Oncol 2008;26: 455–462.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011;29:1855–1863.
   Google Scholar
• Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin's lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrrow Transplant 2006;12:172–183.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Ho V, et al. allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418–425.
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257–264.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803–808.
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1279–1287.
   PubMed Web of Science ®Google Scholar
• Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009;15:109–117.
   PubMed Web of Science ®Google Scholar
• Robinson S, Sureda A, Canals C, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematol 2009;94:230–238.
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671–3677.
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Espanol de Linfomas/Transplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.
   PubMed Web of Science ®Google Scholar
• Center for International Blood and Marrow Transplant, Transplantation Program operated through the U. S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. U.S. transplant data by center report, HL –Hodgkin lymphoma, number of transplants reported in 2009. Last updated: April 5, 2011. Available from: http://bloodcell.transplant.hrsa.gov/RESEARCH/Transplant_Data/US_Tx_Data/Data_by_Center/center.aspx
   Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137–1145.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–4316.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999;10:527–532.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Broussse N, Brice P, et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow up study. Bone Marrow Transplant 2000;25:251–256.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428–434.
   PubMed Web of Science ®Google Scholar
• Cooney JP, Stiff PJ, Toor AA, et al. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 2003;9:177–182.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15:825–828.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–1914.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Kayani I, Edwards N, et al. Donor-lymphocyte infusion modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971–978.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004;33:691–696.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994;83:3377–3383.
   PubMed Web of Science ®Google Scholar
• Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000;96:2712–2716.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30;2183–2189.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119:6379–6381.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120:560–568.
   PubMed Web of Science ®Google Scholar